Isochem is a fully integrated business comprised of research, product/process development, regulatory approvals, pilot scale and full plant-scale production of drug intermediates and active pharma ingredients for major pharmaceutical companies worldwide.
Isochem, which serves the needs of oncology, cardiovascular, infectious, gastrointestinal, neurology and rare diseases, will be a wholly owned subsidiary of PMC Group France.
Its facilities, which cover more than 40 acres, are located at three sites within a 60-mile radius of Paris. The company will be called PMC Isochem SAS and have more than 230 employees.
“This acquisition, coming within two months of the acquisition of the Hyderabad, India-based pharma company YM Drugs and Chemicals by PMC Group International, puts the latter in a solid position to serve all the regulated pharma markets around the world with cost-effective offerings of proprietary drugs, drug intermediates and custom drug research and manufacturing services for a wide range of disease categories,” said Dr. Raj Chakrabarti, executive vice president of PMC Group International.